Corcept Therapeutics
CORT
422 hedge funds and large institutions have $5.87B invested in Corcept Therapeutics in 2025 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 155 increasing their positions, 157 reducing their positions, and 65 closing their positions.
9% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 65
0% more funds holding
Funds holding: 422 → 422 (0)
1% less repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 157
4.34% less ownership
Funds ownership: 78.86% → 74.52% (-4.3%)
36% less capital invested
Capital invested by funds: $9.24B → $5.87B (-$3.37B)
39% less call options, than puts
Call options by funds: $51.5M | Put options by funds: $84.9M
63% less funds holding in top 10
Funds holding in top 10: 16 → 6 (-10)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
+$65M |
| 2 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$59.4M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$55.5M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$41.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$30.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$156M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$64.8M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$51M |
| 4 |
State Street
Boston,
Massachusetts
|
-$31.5M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$31.4M |
CORT Hedge Fund Activity: Q2 2025 in Review
422 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2025, worth a combined $5.87B — down 36% from $9.24B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new CORT positions and 65 closed out — a net gain of 6 holders — while 155 added to existing stakes and 157 trimmed.
The largest buyer was ClearBridge Investments, adding an estimated $65M. The largest seller was BlackRock, cutting an estimated $156M.
- 422 institutional investors held Corcept Therapeutics (CORT) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $5.87B of Corcept Therapeutics stock for Q2 2025, down 36% quarter-over-quarter.
- 71 funds opened new Corcept Therapeutics positions in Q2 2025 and 65 closed out, a net change of +6 holders.
- The largest Corcept Therapeutics buyer in Q2 2025 was ClearBridge Investments, an estimated $65M added.
- The largest Corcept Therapeutics seller in Q2 2025 was BlackRock, an estimated $156M sold.
Based on aggregated 13F filings for Q2 2025.